The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies.
Christopher Ryan Heery
No relevant relationships to disclose
Geraldine Helen O'Sullivan Coyne
No relevant relationships to disclose
Ravi Amrit Madan
No relevant relationships to disclose
Jeffrey Schlom
Honoraria - EMD Serono
Anja von Heydebreck
Employment or Leadership Position - Merck KGaA
Stock Ownership - Merck KGaA
Jean-Marie Cuillerot
Employment or Leadership Position - EMD Serono
Stock Ownership - Bristol-Myers Squibb
Helen Sabzevari
Employment or Leadership Position - EMD Serono
James L. Gulley
No relevant relationships to disclose